Components for enabling immunodection of MT-45 are described including immunogens, antibodies derived from the immunogens, immunoassay methods, detecting agents and kits.

Components for enabling immunodection of MT-45 are described including immunogens, antibodies derived from the immunogens, immunoassay methods, detecting agents and kits.

The present invention provides compounds and methods for modulation of the quorum sensing of bacteria. In an embodiment, the compounds of the present invention are able to act as replacements for naturally occurring bacterial quorum sensing ligands in a ligand-protein binding system; that is, they imitate the effect of natural ligands and produce an agonistic effect. In another embodiment, the compounds of the present invention are able to act in a manner which disturbs or inhibits the naturally occurring ligand-protein binding system in quorum sensing bacteria; that is, they produce an antagonistic effect. The compounds of the present invention comprise N-acylated-homoserine lactones (AHLs) comprised of a wide range of acyl groups.

The present invention provides compounds and methods for modulation of the quorum sensing of bacteria. In an embodiment, the compounds of the present invention are able to act as replacements for naturally occurring bacterial quorum sensing ligands in a ligand-protein binding system; that is, they imitate the effect of natural ligands and produce an agonistic effect. In another embodiment, the compounds of the present invention are able to act in a manner which disturbs or inhibits the naturally occurring ligand-protein binding system in quorum sensing bacteria; that is, they produce an antagonistic effect. The compounds of the present invention comprise N-acylated-homoserine lactones (AHLs) comprised of a wide range of acyl groups.

The present invention relates to the field of polymers used to form coatings at the surface of supports.

More particularly, the invention relates to a polymer having adhesion properties, in particular with regard to an organic or inorganic support, characterized in that it comprises at least one and preferably several consecutive or non-consecutive structural units of formula (I):

##STR00001##

in which: B represents a carbonyl or —NR′— unit with R′ representing a hydrogen atom, a C.sub.1 to C.sub.6 alkyl radical, or a C.sub.5 to C.sub.6 aryl, carbamate or acyl radical; and R represents: a hydrogen atom, a linear or branched, saturated or unsaturated C.sub.1 to C.sub.6 hydrocarbon-based radical which, where appropriate, is substituted with one or more halogen atoms, a C.sub.5 to C.sub.6 aryl radical, or an acyl, acyloxy, alkoxycarbonyl or cyano radical.

Disclosed are compounds of the Formula 1 wherein A is an aromatic moiety; H is a hydrophobic group comprising a main alkyl chain having from about 3 to about 26 carbon atoms and comprising a C.sub.2 or greater alkyl chain branched from the main alkyl chain; and K is a hydrophilic group. ##STR00001##

Disclosed are compounds of the Formula 1 wherein A is an aromatic moiety; H is a hydrophobic group comprising a main alkyl chain having from about 3 to about 26 carbon atoms and comprising a C.sub.2 or greater alkyl chain branched from the main alkyl chain; and K is a hydrophilic group. ##STR00001##

Compounds having formulas (I) to (VIII), salts thereof, or combinations thereof and pharmaceutical compositions comprising one or more these compounds are described herein for the treatment of HIV and neurodegenerative effects caused by HIV. Also provided herein are methods and a kit for inhibiting HIV-1, treating latent HIV in the brain, and preventing HIV-mediated cognitive decline and HIV dementia comprising administering the compounds having the formulas (I) to (VIII) and pharmaceutical compositions comprising the compounds having these formulas. The compounds having formulas I through VIII are curcumin analogs which are advantageously characterized as having anti-retroviral, neuroprotective, anti-glucosidase, and anti-HIV integrase properties. In one aspect, the pharmaceutical composition is delivered intranasally.

Compounds having formulas (I) to (VIII), salts thereof, or combinations thereof and pharmaceutical compositions comprising one or more these compounds are described herein for the treatment of HIV and neurodegenerative effects caused by HIV. Also provided herein are methods and a kit for inhibiting HIV-1, treating latent HIV in the brain, and preventing HIV-mediated cognitive decline and HIV dementia comprising administering the compounds having the formulas (I) to (VIII) and pharmaceutical compositions comprising the compounds having these formulas. The compounds having formulas I through VIII are curcumin analogs which are advantageously characterized as having anti-retroviral, neuroprotective, anti-glucosidase, and anti-HIV integrase properties. In one aspect, the pharmaceutical composition is delivered intranasally.

Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.